On December 28th, Suzhou Linaxin Biotechnology Co., Ltd. held its 2023 annual work conference to summarize the company's work in 2023, identify shortcomings and gaps, analyze the current situation and tasks, and deploy the target tasks and key work for 2024. General Manager Tan Shengwei presented the 2023 annual business work report, and Vice General Manager Zhu Wanjie presided over the meeting.

Tan Shengwei stated that in 2023, the development of Linaxin will be steady and progress will be made, with new breakthroughs in research and innovation. Significant progress has been made in the construction of new platform production lines and medical testing centers. The foundation for production development will be consolidated and solidified, market expansion will gradually open up, quality system construction will be further improved, and brand establishment will gradually strengthen.

Subsequently, management personnel at all levels of the company conducted year-end work reports and personal reports, showcasing their work achievements and insights over the past year, and analyzing their shortcomings and gaps.

In the subsequent recognition process, the company commended outstanding employees and teams. These exemplary individual and collectives have made outstanding contributions to their respective posts, demonstrating the excellent culture of the company. By commending the advanced and motivating all employees to devote themselves to their work with greater enthusiasm.

Tan Shengwei has made comprehensive arrangements for the work in 2024, clarifying the company's development direction and key tasks for the new year. 2024 is the second year of Linaxin's second three-year strategic plan, a crucial year for deepening the implementation of solid foundations, consolidating new development stages, and promoting high-quality development. In 2024, we will focus on core business, deeply cultivate core markets, consolidate market volume, specialize in core technologies, and strive for steady development.

Tan Shengwei signed the "2024 Task Target Responsibility Agreement" with the main responsible persons of various departments, and signed the "2024 Task Military Order" with the main responsible persons of the sales department, aiming to clarify goals, implement responsibilities, stimulate motivation, and ensure the smooth completion of various work tasks in 2024!

Finally, Tan Shengwei stated that Linaxin is embarking on a new journey of struggle. All subsidiaries, departments, and responsible persons at all levels should unify their thoughts and actions with the company's decision-making and deployment regarding business operations, regard market sales as the lifeblood of the enterprise's survival, and regard technological innovation, high-quality and sustainable development as the primary task of the enterprise. According to the company's deployment, strengthen overall coordination of street connections, organize implementation in an orderly manner, manage work projects and lists scientifically, strengthen project tracking, follow up in real time, report daily, summarize weekly, and complete monthly tasks.

In 2024, we will never forget our journey, forge ahead, and strive to write a new chapter in the construction of Linaxin. We will contribute to a Healthy China by 2030 and continue to strive to improve human health!